Amicus Therapeutics Inc

Amicus Therapeutics — FY2020 Earnings Presentation

29 slides from Amicus Therapeutics's earnings presentation, Mar 1, 2021

  1. Slide 1: Full Year 2020 Financial Results Conference Call & Webcast

    Exhibit 99.2 Full Year 2020 Financial Results Conference Call & Webcast March 1, 2021

  2. Slide 2: Forward-Looking Statements

    Introduction 2 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinica

  3. Slide 3: '),l,H,,'.I.I,J.·..' (\V.Allf,• 'U,J .l Rossella:dall'Americaconamore 4J\lbpohi/fomtacoperlabimbade!Mona/di ':A I'lnd…

    3 '),l,H,,'.I.I,J.·..' (\V.Allf,• 'U,J .l Rossella:dall'Americaconamore 4J\lbpohi/fomtacoperlabimbade!Mona/di ':A I'lndirittoazma chance" : ---------yv La cura funziona, Rossella sta iciim'itanoalia pmde za: e al cora presto i ,, ' . r,J m ed c.·t'scf! Ia r:dwia nrorm ;JJ,bJmb,,affeua era un• rdfa m

  4. Slide 4: Introduction

    Introduction 4 PLATFORM & Glycobiology AT-GAA Phase 3 in Pompe Disease Two Clinical-Stage Gene Therapies $483.3M Cash as of 12/31/20 GLOBAL COMMERCIAL ORGANIZATION Robust R&D Engine Nearly 50+ Lysosomal Disorders and More Prevalent Rare Diseases EMPLYEES in 27untries Gene Therapy Protein Engineering

  5. Slide 5: 2021 Key Strategic Priorities

    Introduction 5 2021 Key Strategic Priorities 1 2 3 4 5 Achieve double-digit Galafold growth and revenue $300M to $315M Report data from the AT-GAA Phase 3 PROPEL study and complete BLA and MAA filings for regulatory approvals Advance clinical studies, regulatory discussions and scientific data acros

  6. Slide 6: Galafold Global Launch

    Galafold® (migalastat) Global Launch… …taking a leadership role in the treatment of Fabry disease “We push ideas as far and as fast as possible” - Amicus Belief Statement

  7. Slide 7: Galafold Snapshot

    Galafold: Precision Medicine for Fabry Disease 7 Galafold Snapshot (as of December 31, 2020) One of the Most Successful $260.9M FY20 Galafold Revenue Rare Disease Launches $300M-315M FY21 Global Galafold Revenue 1,384 Amenable Mutations Included in the Label 348 nable Variants in U.S. Label Continue

  8. Slide 8: 2020 Galafold Success

    Galafold: Precision Medicine for Fabry Disease 8 2020 Galafold Success Year-over-Year Sales Growth Quarterly Galafold Sales 2019 Operational Growth FX Impact 2020 3Q19 4Q19 1Q20 2Q20 3Q20 4Q20 2019 vs 2020 $70.9M $67M $62M $61M $55M $49M +1% $260.9M $182M +42% Growth remains strong with Q4 revenue o

  9. Slide 9: Galafold Global Commercial Momentum

    Galafold: Precision Medicine for Fabry Disease 9 Galafold Global Commercial Momentum FY20 Strength Reflects Continued Strength with 1,400+ Treated Patients Strong patient demand and several new launch countries anticipated in 2021 Global mix of switch (60%) and previously untreated patients (40%) Co

  10. Slide 10: Galafold Geographic Growth

    Galafold: Precision Medicine for Fabry Disease 10 Galafold Geographic Growth Expect to add at least 5 additional countries in 2021 Expansion into multiple new markets throughout 2020 including: Poland, Iceland, Luxembourg, Argentina, Greece Regulatory approval in 40+ countries and commercial sales i

  11. Slide 11: Outlook for 2021

    Galafold: Precision Medicine for Fabry Disease 11 Outlook for 2021 • 2020 execution lays a solid foundation and global demand remains strong with continued growth anticipated in 2021 and beyond New Galafold patient additions slowed in Q4 due to COVID reemergence and resulting in increased lag time b

  12. Slide 12: Galafold Opportunity

    Galafold: Precision Medicine for Fabry Disease 12 Galafold Opportunity $1B+ Opportunity With inherent Fabry market growth and our work to improve screening and diagnosis, Galafold has the potential to drive $1B+ $500M+ Projected Revenue Peak annual revenue at peak $261M 2023 Durable growth and incre

  13. Slide 13: AT-GAA: Next Potential Standard of Care for Pompe Disease

    AT-GAA: Next Potential Standard of Care for Pompe Disease “We encourage and embrace constant innovation” - Amicus Belief Statement

  14. Slide 14: Unmet Need in Pompe Disease Today

    AT-GAA for Pompe Disease 1144 Unmet Need in Pompe Disease Today There is an initial positive effect on the most important outcome measures, however, a more limited long-term benefit of stabilization of the clinical course under ERT for many patients over a long period. Though, accordingto our data,

  15. Slide 15: PROPEL Topline Results: Overall Population

    AT-GAA for Pompe Disease 15 PROPEL Topline Results: Overall Population (n=122) 6MWD (m) FVC (% predicted) NOTES: Baseline is Mean (STDEV); CFBL is Mean LOCF (SE); P-values are nominal 2-sided; FVC data normally distributed and p–values are from ANCOVA. Results exclude one clinically implausible pati

  16. Slide 16: PROPEL Topline Results: ERT Experienced Population

    AT-GAA for Pompe Disease 16 PROPEL Topline Results ERT Experienced Population (n=95) 6MWD (m): Change from baseline (n=65, n=30) FVC (% predicted): Change from baseline (n=65, n=30) 2.0 1.5 30 1.0 25 0.5 0.0 20 -0.5 -1.0 -1.5 15 10 -2.0 -2.5 5 -3.0 -3.5 -4.0 0 -2 -4 -6 -8 -4.5 -5.0 Bas eline Week 12

  17. Slide 17: Primary, Key Secondary and Biomarker Endpoint Heat Map

    AT-GAA for Pompe Disease 17 Primary, Key Secondary and Biomarker Endpoint Heat Map All Patients & ERT Experienced Patients Overall Population ERT Experienced Population Note: * Nominal P-value <0.05; based on LOCF means Alglucosidase alfa AT-GAA Motor Function 6MWD* GSGC* Pulmonary Function FVC* Mus

  18. Slide 18: Post Hoc Non-Inferiority Analyses

    AT-GAA for Pompe Disease 18 Post Hoc Non-Inferiority Analyses p-value NOTE1: 6MWD results are based on MMRM analysis using observed cases and FV results are based on ANCOVA using LOCF. NOTE2: As Lumizyme did not show statistical significance versus placebo for 6MWD, the NI margins were not statistic

  19. Slide 19: AT-GAA: Key Takeaways

    AT-GAA for Pompe Disease 19 AT-GAA: Key Takeaways • • Rolling BLA submission expected to complete in Q2 Other key regulatory submissions for approval throughout 2021 including MAA in Europe Potential for early approval under EAMS framework with Priority Innovative Medicines Designation in UK 150+ pa

  20. Slide 20: Next Generation Gene Therapy Platform

    Next Generation Gene Therapy Platform “We have a duty to obsolete our own technologies” - Amicus Belief Statement

  21. Slide 21: Next Generation Gene Therapy Platform Pipeline

    Next Generation Gene Therapy Platform 21 *Exclusive license from Ultragenyx for Japanese rights to Mepsevii™, investigator-sponsored trial in Japan underway DISCOVERY PRECLINICAL PHASE 1/2 PHASE 3 REGULATORY COMMERCIAL Fabry Franchise Galafold®(migalastat) Monotherapy Fabry Gene Therapy PENN Pompe F

  22. Slide 22: CLN3 Batten Disease Gene Therapy AT-GTX-502

    Next Generation Gene Therapy Platform 22 CLN3 Batten AT-GTX-502 Disease Gene Therapy UBDRS=Unified Batten Disease Rating Scale. a Scheduled month 12 in-person UBDRS assessment was impacted by the COVID-19 pandemic. •Batten disease is a group of disorders known as neuronal ceroid lipofuscinoses (NCLs

  23. Slide 23: Financial Summary

    Financial Summary “We are business led and science driven” - Amicus Belief Statement

  24. Slide 24: 2020 Select Financial Results

    Financial Summary 24 2020 Select Financial Results (in thousands, except per share data) Dec. 31, 2020 Dec. 31, 2019 Product Revenue $260,886 $182,237 Cost of Goods Sold 31,044 21,963 R&D Expense 308,443 286,378 SG&A Expense 156,407 169,861 Changes in Fair Value of Contingent Consideration 3,144 3,2

  25. Slide 25: Financial Outlook: Key Takeaways

    Financial Summary 25 Financial Outlook: Key Takeaways • Galafold revenue in 2020 was $260.9 million, exceeding the Company’s guidance • 2020 Non-GAAP Operating Expenses of $415.7M in line with guidance of $410 million to $420 million • Non-GAAP operating expense guidance for 2021 is expected to rema

  26. Slide 26: Closing Remarks

    Closing Remarks “We are business led and science driven” - Amicus Belief Statement

  27. Slide 27: Thank You

    ThankYou “Our passion for making a difference unites us” -Amicus Belief Statement

  28. Slide 28: Appendix

    Appendix

  29. Slide 29: Reconciliation of Non-GAAP Financial Measures

    Amicus Therapeutics, Inc. Reconciliation ofNon-GAAP Financial i\•leasures (in thousands) December31 2020 s476,840 2019 2018 s Total operating expenses - as reported GAAP Research and d evelopment: Share-based compensation Asset acquisition related expenses for in- processR&D Selling, general and adm

Amicus Therapeutics — FY2020 Earnings Presentation on 6ix